New research co-authored by researchers from Harvard T.H. Chan School of Public Health found seniors over age 65 at the highest risk for severe COVID-19 have often been the least likely to receive innovative monoclonal antibody (mAbs) treatments.
But during the ongoing COVID-19 pandemic, anti-SARS-CoV-2 mAbs have been in short supply in the U.S., creating allocation conflicts at the local level.
Read More
